
1. expert rev clin immunol. 2011 may;7(3):273-81. doi: 10.1586/eci.11.20.

leflunomide renal transplantation.

chon wj(1), josephson ma.

author information: 
(1)section nephrology, department medicine, university chicago, 5841
south maryland avenue, mc 5100, chicago, il 60637, usa.

leflunomide synthetic isoxazole-derivative drug possesses both
immunosuppressive antiviral properties. although us fda-approved
indication treatment rheumatoid arthritis, accumulating clinical
experience addition animal study data makes appealing option for
patients need reduction immunosuppression setting of
resistant cytomegalovirus infection bk virus nephropathy, renal
transplant recipients chronic allograft dysfunction. concern over
adverse effects hepatotoxicity hemolytic anemia cannot ignored and
there yet prospective randomized trial use in
transplantation, careful usage close monitoring may provide best
chance patients risk allograft rejection time of
immunosuppressive reduction attempt eradicate bk virus or
cytomegalovirus. present time, use first-line agent lieu of
mycophenolate mofetil sirolimus cannot recommended.

doi: 10.1586/eci.11.20 
pmid: 21595593  [indexed medline]

